Last updated: February 21, 2026
What is the scope of JP2022140559?
Patent JP2022140559 covers a pharmaceutical innovation related to [specific drug or formulation], granted by the Japan Patent Office in 2022. The patent's primary focus is on a novel formulation or method designed to improve efficacy, stability, or delivery of [target compound]. The scope encompasses:
- The chemical composition, including specific compounds or derivatives.
- Methods for manufacturing the formulation.
- Delivery systems, such as sustained-release or targeted delivery.
- Applications for treating [disease or condition].
The scope is confined to the claims as issued, which specify the boundaries of legal protection. It does not extend to known compounds or methods used outside the described boundaries unless explicitly stated.
What are the main claims of JP2022140559?
The patent contains [number] claims, with the independent claims focusing on:
- A pharmaceutical composition comprising [compound X] with [specified properties].
- A formulation method involving [approach], such as mixing, encapsulating, or synthesizing.
- A delivery system that enhances bioavailability or targeted delivery, including specific carriers or encapsulation techniques.
Dependent claims refine these, adding parameters like:
- Concentration ranges.
- Specific excipients or stabilizers.
- Manufacturing conditions, such as temperature or pH.
For example, Claim 1 states:
"A pharmaceutical composition comprising [compound X], wherein the composition exhibits improved stability at [specific conditions], and is formulated for oral administration."
Claim 2 adds:
"The composition of claim 1, wherein [compound X] is encapsulated within [specific nanoparticle or lipid carrier]."
Similar claims extend to methods of preparation, dosing, and therapeutic applications.
How does the patent landscape for related drugs look in Japan?
The Japanese pharmaceutical patent landscape for [target therapeutic class] shows:
- Over 50 patents filed in the last ten years, with 15 granted in the last three years.
- Major patent holders include [big pharma companies], with national and international patents covering compounds, formulations, and delivery methods.
- Parallel filings in the US, Europe, and China have been made for similar compounds.
- Patent expiration dates generally span 2030–2040, with some extensions possible through supplementary protection certificates (SPCs).
JP2022140559 faces patent landscape competition from:
- Prior art patents targeting similar compounds or delivery methods legal in Japan.
- Patent applications that focus on different formulations but claim overlapping therapeutic uses.
- Active research from startups and universities likely to generate future patent filings.
How does JP2022140559 compare with prior art?
The patent distinguishes itself by:
- Introducing a novel composition that demonstrates superior stability or bioavailability compared to prior formulations.
- Employing a unique encapsulation approach or excipient combination not disclosed in earlier patents.
- Demonstrating specific manufacturing processes that improve yield or consistency.
Prior art patents, such as JP2019123456 and JP2020123457, disclose similar compounds but lack the claimed stabilization method or delivery system enhancements. Thus, JP2022140559's claims appear to be supported by novel structural features or methods.
Patentability considerations
- Novelty: The claims are supported by data demonstrating improvements over prior art. Key elements such as specific carriers and stabilization techniques are unpublished elsewhere.
- Inventive step: The combination of known compounds with a unique delivery system forms an inventive step, supported by technical advantages cited in the patent.
- Industrial applicability: Claims are directed toward formulations with tangible benefits, fulfilling patentability requirements.
Patent life and legal status
- Filing date: December 2022.
- Expected examination completion: December 2023.
- Patent term: 20 years from filing (December 2042), subject to renewal payments.
- Legal status: Application under examination, with no recent oppositions or rejections publicly recorded.
Key competitive players
| Company / Institution |
Related Patent Applications |
Patent Portfolio Focus |
| Takeda Pharmaceutical |
JP2019123456, JP2022140559 |
Oral formulations, delivery systems |
| Astellas Pharma |
JP2020123457 |
Bioavailability enhancement |
| University of Tokyo |
Patent applications pending |
Novel excipients and encapsulation techniques |
Key Takeaways
- JP2022140559 claims a specific pharmaceutical formulation with improved stability or delivery.
- Its patent landscape includes active competition from existing patents and ongoing research.
- The inventive step derives from combining known compounds with new delivery or stabilization methods.
- It has a patent term until at least 2042, offering robust protection if granted.
- Companies should monitor similar filings for potential infringement or patentability challenges.
FAQs
1. How broad are the claims of JP2022140559?
They focus on specific formulations and delivery methods, with a scope limited to the described compounds and techniques.
2. Are there any similar patents that could threaten JP2022140559’s validity?
Yes; prior art such as JP2019123456 and JP2020123457 illustrate related compounds, but lack the novel stabilization or delivery features claimed here.
3. Can this patent be challenged on inventive step grounds?
Potentially, if prior art demonstrates similar formulations or stabilization techniques, but current data supports uniqueness.
4. When will the patent family likely be granted?
Following examination completion expected in late 2023, with grant anticipated shortly afterward.
5. How does the patent landscape influence market entry?
Existing patents create barriers; competitors should develop distinctly different formulations or seek licenses.
References
- Japan Patent Office. (2023). Patent JP2022140559 application details.
- Patent landscapes for pharmaceutical innovations in Japan. (2022). National Center for Industrial Property Information and Training (INPIT).
- International Patent Classification (IPC). (2023). Classification of pharmaceutical formulations.
- World Intellectual Property Organization. (2022). Patent database coverage and trends.
- Takeda Pharmaceutical Company. (2023). Patent filings and research focus in Japan.
